Proactive Investors - Run By Investors For Investors

Alliance Pharma grows strongly as overseas revenues pass domestic sales for the first time

“In 2018 we continued to deliver on our strategy, with strong sales and profit growth, led by our international star brands and acquisitions. 2018 marked a milestone in the internationalisation of Alliance in that, for the first time, our overseas sales exceeded those in the UK,” said CEO Peter Butterfield
map of world drawn using pills
The company now has a truly global footprint

Alliance Pharma PLC (LON:APH) posted strong growth, boosted by acquisitions, as overseas sales surpassed domestic revenues for the first time ever.

The company’s star international brands performed well, led by Kelo-cote, a skin treatment.

Income from Vamousse, for head lice, grew 16% under the company’s ownership, while Nizoral, a Johnson & Johnson medicated shampoo, for which Alliance acquired the Asia-Pacific rights last June for £60mln, traded in line with expectations. Its integration is progressing well, investors were told.

Xonvea, for morning sickness, was launched in October, and it is now starting to gain formulary inclusions, Alliance said.

Further acquisitions

Chief executive Peter Butterfield added that 2019 had started well and hinted at further acquisitions as he told the market the group would look to deploy its strong cash flow to further develop the business.

Turning to the finances, statutory turnover was up 16% to £118.2mln for the year to December 31, while the “see-through” figure was ahead 22% at £124mln. That latter number included a financial contribution from the recently-acquired Nizoral shampoo brand. Like-for-like revenues, which strip out the impact of recent purchases, were up 4%.

Underlying earnings (EBITDA) rose 19% to £32.4mln, while free cash flow was strong at £16.1mln. At the period-end net debt was £85.5mln as leverage fell to 2.33-times from 2.46.

Alliance said it will hike the dividend 10% to 0.977p, giving a total of 1.464p. The payout is covered more than three-times by underlying earnings.

“In 2018 we continued to deliver on our strategy, with strong sales and profit growth, led by our international star brands and acquisitions. 2018 marked a milestone in the internationalisation of Alliance in that, for the first time, our overseas sales exceeded those in the UK,” said CEO Butterfield.

“The acquisition of Nizoral brings increased scale and opportunities for us in the Asia Pacific region and, together with the creation of a trading operation in the US, further increases our international footprint, whilst the UK approval of Xonvea offers further organic growth prospects for the group.”

View full APH profile View Profile

Alliance Pharma PLC Timeline

Newswire
January 21 2019

Related Articles

scientists in a lab
January 30 2019
The technology first drew the attention of ChemioCare CEO Pedro Lichtinger years ago while he oversaw Pfizer's global primary care business
pills
January 15 2019
Under former chief executive Peter George and his successor Shaun Chilton, Clinigen has been transformed via a series of well-judged, quickly integrated and cash generative acquisitions
scientist in a lab
April 12 2019
Danish giant Novo Nordisk recently signed up to use its NDD platform, and bosses expect more collaboration deals in the coming months
Copyright © Proactiveinvestors.com, 2019. All Rights Reserved - Proactive Investors North America Inc., Proactive Investors LLC

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use